AstraZeneca Pharmaceuticals LP has again sued Torrent Pharmaceuticals Ltd. over efforts to produce a copycat version of schizophrenia treatment Seroquel XR®, claiming that the generics maker's abbreviated new drug application (ANDA) for a lower strength of the drug also infringes a patent. AstraZeneca lodged filed suit Tuesday in the U.S. District Court for the District of New Jersey, seeking to block India-based Torrent and its U.S. subsidiary Torrent Inc. from manufacturing a 50 mg strength version of generic Seroquel XR® before U.S. Patent Number 5,948,437 expires in May 2017. The '437 patent, titled “Pharmaceutical compositions using thiazepine,” was issued in September 1999 and claims sustained release formulations of quetiapine fumarate, the active ingredient in Seroquel XR, as well as processes for preparing and using such formulations, according to the complaint. AstraZeneca is represented by Finnegan.
Award/Ranking
Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars
October 5, 2023
Press Release
Finnegan Earns Law360’s Practice Group of the Year for Intellectual Property
January 18, 2023
Award/Ranking
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.